National Taiwan University    |    NTU, College of Medicine
NTU, Department of Pharmacy
Graduate Institute of Clinical Pharmacy
Drug Research Center    |     Ching Kang Foundation
Center for Innovative Therapeutics Discovery
Alumni    |    Alumni in North America    |    AASP    |    MRBS
© copyright 2014 SP, NTU. All Rights Reserved.
No.33, Linsen S. Rd., Zhongzheng Dist., Taipei City 100, Taiwan (R.O.C.)
TEL : (02)3366-8750~4    FAX : (02)2391-9098
Web person in charge: Yu-Chen Ho / Tang-Yih Hsu
Contact Phone : (02)33668754 / (02)33668743
Latest Update : 2017 / 11 / 10
Privacy & Security Policy
Faculty
back
Ji-Wang Chern
Title:Distinguished Professor / Director, Center for innovative Therapeutics Discovery
TEL:+886-2-3366-8697     Email:jwchern@ntu.edu.tw
Web Site
PortfolioPortfolio ResearchResearch
Education:Ph.D in Medicinal Chemistry, University of Michigan,USA
Experience:Professor and Director, Medical Laboratories, National Defense Medical Center (1986-1996).
Chairman, School of Pharmacy (2000-2005).
Dean, Office of Research and Development, National Taiwan University (2006~ 2012).
Chairman, Center for innovative Therapeutics Discovery, NTU (2013~now).
Honor:Fellow, American Association for the Advancement of Science, 2001.
Research Areas:Design and developement of new drugs, Heterocyclic Chemistry, Pharmaceutical Chemistry
Lab Focus:This laboratory is focused on the new anticancer, antiviral, CNS and cardio- vascular drug discovery. The approaches are taken by either generating the hypothetic 3D structure through existing compounds through computer modeling program or directly using the X-Ray 3D structure of enzymatic protein, followed a virtually high through-put screening via docking through a variety of data bases to provide a new ead compound. Then the traditional approaches toward the lead optimization for new drug development are applied . On the basis of these approaches , current ongoing research projects include : design and synthesis of selective A1a-adrenoceptor and 5a-reductase inhibitor for the treatment of benign hypertrophy , design and synthesis of helicase inhibitors against hepatitis C, design and synthesis of adenosine A1 agonist for the treatment of arrhythmia,design and synthesis multi-drug resistance tumor reversing agents, and design and synthesis of tyrosine kinase inhibitors.